Analysts Offer Insights on Healthcare Companies: Calithera Bio (NASDAQ: CALA) and Xoma Corp (NASDAQ: XOMA)

By Austin Angelo

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Calithera Bio (NASDAQ: CALA) and Xoma Corp (NASDAQ: XOMA) with bullish sentiments.

Calithera Bio (NASDAQ: CALA)

In a report released today, Shaunak Deepak from H.C. Wainwright reiterated a Buy rating on Calithera Bio (NASDAQ: CALA), with a price target of $19. The company’s shares closed last Friday at $14.20.

According to TipRanks.com, Deepak is ranked 0 out of 5 stars with an average return of -17.8% and a 28.0% success rate. Deepak covers the Healthcare sector, focusing on stocks such as Lexicon Pharmaceuticals, Karyopharm Therapeutics, and CytomX Therapeutics Inc.

Calithera Bio has an analyst consensus of Moderate Buy, with a price target consensus of $17.50.

Xoma Corp (NASDAQ: XOMA)

Xoma Corp (NASDAQ: XOMA) received a Buy rating and a $15 price target from H.C. Wainwright analyst Carol Werther today. The company’s shares closed last Friday at $6.42.

According to TipRanks.com, Werther is a 5-star analyst with an average return of 24.5% and a 56.9% success rate. Werther covers the Healthcare sector, focusing on stocks such as ImmunoCellular Therapeutics, Ionis Pharmaceuticals Inc, and Aevi Genomic Medicine Inc.

Xoma Corp has an analyst consensus of Moderate Buy, with a price target consensus of $12.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.